An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

(2018) G N Hortobagyi et al.   ANNALS OF ONCOLOGY

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Modeling drug passage into human milk

(2016) PO Anderson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

(2016) C. M. Nijenhuis et al.   DRUG METABOLISM REVIEWS

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gender Specific Drug Metabolism of PF-02341066 in Rats — Role of Sulfoconjugation

(2010) Wei-Zhu Zhong et al.   CURRENT DRUG METABOLISM

A Simple Liquid Chromatography-Tandem Mass Spectrometry Method to Determine Relative Plasma Exposures of Drug Metabolites across Species for Metabolite Safety Assessments

(2010) H. Gao et al.   DRUG METABOLISM AND DISPOSITION

Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development

(2009) Eric G. Solon et al.   AAPS Journal